RSCM
RIGL icon

Rock Springs Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Rock Springs Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-492,149
Closed -$14.7M – 137
2022
Q1 		$14.7M Buy
492,149
+6,129
+1% +$166K 0.37% 70
2021
Q4 		$12.9M Buy
486,020
+6,680
+1% +$202K 0.3% 83
2021
Q3 		$17.4M Buy
479,340
+3,850
+0.8% +$152K 0.37% 78
2021
Q2 		$20.6M Buy
475,490
+1,290
+0.3% +$48.7K 0.41% 75
2021
Q1 		$16.2M Sell
474,200
-89
-0% -$3.52K 0.35% 82
2020
Q4 		$16.6M Hold
474,289
– – 0.35% 87
2020
Q3 		$11.4M Sell
474,289
-115,475
-20% -$2.84M 0.29% 92
2020
Q2 		$10.8M Buy
589,764
+39,764
+7% +$715K 0.3% 100
2020
Q1 		$8.58M Buy
550,000
+210
+0% +$4.47K 0.35% 79
2019
Q4 		$11.8M Buy
549,790
+129,790
+31% +$2.67M 0.37% 80
2019
Q3 		$7.85M Hold
420,000
– – 0.31% 85
2019
Q2 		$11M Hold
420,000
– – 0.4% 80
2019
Q1 		$10.8M Hold
420,000
– – 0.42% 76
2018
Q4 		$9.66M Buy
420,000
+7,500
+2% +$212K 0.46% 71
2018
Q3 		$13.2M Buy
412,500
+17,500
+4% +$525K 0.48% 66
2018
Q2 		$11.2M Buy
395,000
+137,500
+53% +$4.89M 0.43% 78
2018
Q1 		$9.12M Buy
257,500
+10,000
+4% +$400K 0.39% 82
2017
Q4 		$9.6M Buy
247,500
+147,500
+148% +$5.61M 0.44% 75
2017
Q3 		$2.54M Hold
100,000
– – 0.12% 124
2017
Q2 		$2.73M Hold
100,000
– – 0.14% 117
2017
Q1 		$3.31M Hold
100,000
– – 0.19% 106
2016
Q4 		$2.38M Sell
100,000
-81,000
-45% -$2.32M 0.16% 108
2016
Q3 		$6.64M Buy
181,000
+6,000
+3% +$172K 0.42% 70
2016
Q2 		$3.9M Buy
175,000
+28,595
+20% +$711K 0.29% 93
2016
Q1 		$3.04M Buy
146,405
+36,405
+33% +$898K 0.26% 102
2015
Q4 		$3.33M Buy
+110,000
New +$3.34M 0.25% 100

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rock Springs Capital Management's RIGL Position: Q2 2022 in Review

Rock Springs Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 492,149 shares — an estimated $14.7M sold.

Rock Springs Capital Management first reported a position in RIGL in Q4 2015 and held it in 26 quarters. The position peaked at $20.6M in Q2 2021. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Rock Springs Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Rock Springs Capital Management sold 492,149 Rigel Pharmaceuticals shares in Q2 2022, an estimated $14.7M.
  • Rock Springs Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2015 and held it in 26 quarters.
  • Rock Springs Capital Management's Rigel Pharmaceuticals position peaked at $20.6M in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Rock Springs Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.